These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36890168)

  • 1. Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design.
    Loos C; Coccia M; Didierlaurent AM; Essaghir A; Fallon JK; Lauffenburger D; Luedemann C; Michell A; van der Most R; Zhu AL; Alter G; Burny W
    NPJ Vaccines; 2023 Mar; 8(1):34. PubMed ID: 36890168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants.
    Budroni S; Buricchi F; Cavallone A; Bourguignon P; Caubet M; Dewar V; D'Oro U; Finco O; Garçon N; El Idrissi M; Janssens M; Leroux-Roels G; Marchant A; Schwarz T; Van Damme P; Volpini G; van der Most R; Didierlaurent AM; Burny W
    NPJ Vaccines; 2021 May; 6(1):78. PubMed ID: 34021167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans.
    Burny W; Callegaro A; Bechtold V; Clement F; Delhaye S; Fissette L; Janssens M; Leroux-Roels G; Marchant A; van den Berg RA; Garçon N; van der Most R; Didierlaurent AM;
    Front Immunol; 2017; 8():943. PubMed ID: 28855902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans.
    Burny W; Marchant A; Hervé C; Callegaro A; Caubet M; Fissette L; Gheyle L; Legrand C; Ndour C; Tavares Da Silva F; van der Most R; Willems F; Didierlaurent AM; Yarzabal J;
    Vaccine; 2019 Mar; 37(14):2004-2015. PubMed ID: 30850240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial.
    Leroux-Roels G; Marchant A; Levy J; Van Damme P; Schwarz TF; Horsmans Y; Jilg W; Kremsner PG; Haelterman E; Clément F; Gabor JJ; Esen M; Hens A; Carletti I; Fissette L; Tavares Da Silva F; Burny W; Janssens M; Moris P; Didierlaurent AM; Van Der Most R; Garçon N; Van Belle P; Van Mechelen M
    Clin Immunol; 2016 Aug; 169():16-27. PubMed ID: 27236001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
    Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
    Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
    Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial.
    Rümke HC; Richardus JH; Rombo L; Pauksens K; Plaßmann G; Durand C; Devaster JM; Dewé W; Oostvogels L
    BMC Infect Dis; 2013 Jul; 13():348. PubMed ID: 23890405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
    Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines.
    Del Giudice G; Rappuoli R; Didierlaurent AM
    Semin Immunol; 2018 Oct; 39():14-21. PubMed ID: 29801750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine.
    Fochesato M; Dendouga N; Boxus M
    Hum Vaccin Immunother; 2016 Aug; 12(8):2092-2095. PubMed ID: 26933767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of AS03 and Alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice.
    Yam KK; Gupta J; Allen EK; Burt KR; Beaulieu É; Mallett CP; Burt DS; Ward BJ
    Vaccine; 2016 Mar; 34(12):1444-51. PubMed ID: 26873056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.
    Baz M; Samant M; Zekki H; Tribout-Jover P; Plante M; Lanteigne AM; Hamelin ME; Mallett C; Papadopoulou B; Boivin G
    Clin Vaccine Immunol; 2012 Feb; 19(2):209-18. PubMed ID: 22190392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial.
    Howard LM; Hoek KL; Goll JB; Samir P; Galassie A; Allos TM; Niu X; Gordy LE; Creech CB; Prasad N; Jensen TL; Hill H; Levy SE; Joyce S; Link AJ; Edwards KM
    PLoS One; 2017; 12(1):e0167488. PubMed ID: 28099485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.
    Jackson LA; Campbell JD; Frey SE; Edwards KM; Keitel WA; Kotloff KL; Berry AA; Graham I; Atmar RL; Creech CB; Thomsen IP; Patel SM; Gutierrez AF; Anderson EL; El Sahly HM; Hill H; Noah DL; Bellamy AR
    JAMA; 2015 Jul; 314(3):237-46. PubMed ID: 26197184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
    Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
    Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low hemagglutinin antigen dose influenza vaccines adjuvanted with AS03 alter the long-term immune responses in BALB/c mice.
    Yam KK; Brewer A; Bleau V; Beaulieu É; Mallett CP; Ward BJ
    Hum Vaccin Immunother; 2017 Mar; 13(3):561-571. PubMed ID: 27768511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
    Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
    Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
    Yang WH; Dionne M; Kyle M; Aggarwal N; Li P; Madariaga M; Godeaux O; Vaughn DW
    Vaccine; 2013 Sep; 31(40):4389-97. PubMed ID: 23856331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice.
    Grigoryan L; Lee A; Walls AC; Lai L; Franco B; Arunachalam PS; Feng Y; Luo W; Vanderheiden A; Floyd K; Wrenn S; Pettie D; Miranda MC; Kepl E; Ravichandran R; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; Coffman RL; Novack D; Kleanthous H; O'Hagan DT; van der Most R; McLellan JS; Suthar M; Veesler D; King NP; Pulendran B
    NPJ Vaccines; 2022 May; 7(1):55. PubMed ID: 35606518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.